We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Selcia and Gilead Sciences Extend Liver Disease Drug Discovery Collaboration
News

Selcia and Gilead Sciences Extend Liver Disease Drug Discovery Collaboration

Selcia and Gilead Sciences Extend Liver Disease Drug Discovery Collaboration
News

Selcia and Gilead Sciences Extend Liver Disease Drug Discovery Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Selcia and Gilead Sciences Extend Liver Disease Drug Discovery Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Dr. William Lee, Senior Vice President, Research at Gilead Sciences, commented: “We are pleased to announce the continued research collaboration with Selcia in this very important therapeutic area for Gilead.  Scientists from both companies have interacted well together and have made successful progress against some difficult targets. We are looking forward to the collaboration delivering candidates for clinical studies in the foreseeable future”.

Commenting on the announcement, Selcia’s Managing Director, Dr. Hans Fliri said: “We are delighted to build on our strong collaborative relationship with Gilead in this challenging research area and important therapeutic indication.  This represents a significant step forward in the development of Selcia’s Discovery services and further cements our position as a strategic and trusted partner for integrated drug discovery.  We look forward to continuing to support Gilead in their search for new drugs to treat liver diseases and in fulfilling their longer term objectives”.

Advertisement